Glaukos Corporation (NYSE:GKOS) Given Average Rating of “Moderate Buy” by Analysts

Shares of Glaukos Corporation (NYSE:GKOS) have earned an average rating of “Moderate Buy” from the sixteen research firms that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $133.6923.

GKOS has been the subject of several recent research reports. Wall Street Zen downgraded Glaukos from a “buy” rating to a “hold” rating in a report on Saturday. William Blair upgraded shares of Glaukos to a “strong-buy” rating in a research note on Friday, January 30th. The Goldman Sachs Group reiterated a “buy” rating and issued a $138.00 target price on shares of Glaukos in a report on Friday, January 9th. Citigroup boosted their price target on shares of Glaukos from $113.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Finally, Stephens upped their price objective on shares of Glaukos from $115.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, January 2nd.

Glaukos Price Performance

Shares of NYSE GKOS opened at $120.41 on Monday. The stock has a market cap of $6.92 billion, a price-to-earnings ratio of -36.93 and a beta of 0.70. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.06 and a current ratio of 4.69. Glaukos has a fifty-two week low of $73.16 and a fifty-two week high of $142.95. The firm’s 50-day simple moving average is $115.30 and its 200 day simple moving average is $99.01.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Tuesday, February 17th. The medical instruments supplier reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). The company had revenue of $143.12 million for the quarter, compared to the consensus estimate of $132.16 million. Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.The business’s revenue for the quarter was up 35.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.40) earnings per share. As a group, research analysts anticipate that Glaukos will post -1.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Marc Stapley sold 15,000 shares of the stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $127.71, for a total transaction of $1,915,650.00. Following the completion of the sale, the director directly owned 37,449 shares of the company’s stock, valued at approximately $4,782,611.79. This trade represents a 28.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Joseph E. Gilliam sold 10,498 shares of Glaukos stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $127.68, for a total value of $1,340,384.64. Following the sale, the chief operating officer owned 92,366 shares in the company, valued at $11,793,290.88. This trade represents a 10.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 310,315 shares of company stock valued at $36,011,634 over the last quarter. Corporate insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Glaukos

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. UMB Bank n.a. grew its position in shares of Glaukos by 102.6% during the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 158 shares during the period. First Horizon Corp lifted its stake in Glaukos by 1,715.4% in the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 223 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in Glaukos in the fourth quarter valued at approximately $28,000. Larson Financial Group LLC grew its holdings in Glaukos by 62.0% during the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 132 shares during the period. Finally, REAP Financial Group LLC purchased a new stake in Glaukos in the third quarter worth $40,000. 99.04% of the stock is owned by hedge funds and other institutional investors.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.